GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (NYSE:GSK) » Definitions » Cyclically Adjusted FCF per Share

GSK (GSK) Cyclically Adjusted FCF per Share : $3.50 (As of Dec. 2023)


View and export this data going back to 1987. Start your Free Trial

What is GSK Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GSK's adjusted free cash flow per share for the three months ended in Dec. 2023 was $1.483. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $3.50 for the trailing ten years ended in Dec. 2023.

During the past 12 months, GSK's average Cyclically Adjusted FCF Growth Rate was -2.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 3.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GSK was 83.40% per year. The lowest was -0.60% per year. And the median was 5.60% per year.

As of today (2024-04-27), GSK's current stock price is $41.11. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $3.50. GSK's Cyclically Adjusted Price-to-FCF of today is 11.75.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 19.16. The lowest was 9.39. And the median was 13.05.


GSK Cyclically Adjusted FCF per Share Historical Data

The historical data trend for GSK's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted FCF per Share Chart

GSK Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.21 3.39 3.50 3.42 3.50

GSK Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.42 3.44 3.54 3.33 3.50

Competitive Comparison of GSK's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.



GSK Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.483/130.0000*130.0000
=1.483

Current CPI (Dec. 2023) = 130.0000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.493 99.300 0.645
201406 0.323 99.800 0.421
201409 0.712 100.000 0.926
201412 1.321 99.900 1.719
201503 0.004 99.600 0.005
201506 -0.158 100.100 -0.205
201509 0.030 100.200 0.039
201512 0.624 100.400 0.808
201603 -0.084 100.400 -0.109
201606 0.555 101.000 0.714
201609 0.852 101.500 1.091
201612 1.404 102.200 1.786
201703 0.457 102.700 0.578
201706 0.259 103.500 0.325
201709 0.946 104.300 1.179
201712 1.477 105.000 1.829
201803 0.359 105.100 0.444
201806 0.661 105.900 0.811
201809 1.082 106.600 1.320
201812 2.211 107.100 2.684
201903 0.238 107.000 0.289
201906 0.479 107.900 0.577
201909 1.270 108.400 1.523
201912 1.740 108.500 2.085
202003 0.384 108.600 0.460
202006 1.469 108.800 1.755
202009 0.137 109.200 0.163
202012 2.199 109.400 2.613
202103 -0.016 109.700 -0.019
202106 0.513 111.400 0.599
202109 0.924 112.400 1.069
202112 2.109 114.700 2.390
202203 1.278 116.500 1.426
202206 0.571 120.500 0.616
202209 0.466 122.300 0.495
202212 0.687 125.300 0.713
202303 -0.283 126.800 -0.290
202306 0.381 129.400 0.383
202309 1.032 130.100 1.031
202312 1.483 130.000 1.483

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


GSK  (NYSE:GSK) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=41.11/3.5
=11.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of GSK was 19.16. The lowest was 9.39. And the median was 13.05.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GSK Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK (GSK) Business Description

Industry
Address
980 Great West Road, Brentford, Middlesex, GBR, TW8 9GS
In the pharmaceutical industry, GSK ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.